Effects of Androgen Deprivation Therapy Duration on Health-Related Quality of Life, Physical Activity, Anxiety and Depression Levels in Patients with Intermediate- and High-Risk Prostate Cancer

Objective: Androgen deprivation therapy (ADT) is the common and important treatment for patients with intermediate- or high-risk prostate cancer (PCa). Androgen deprivation therapy can lead to serious side effects in short and long term duration in life of patients. The aim of the study was to investigate the effect of ADT on physical activity, mental health, and quality of life in intermediate- and high-risk PCa patients.

Methods: Seventy-eight patients (34 intermediate risk and 44 high risk) were included in this study. Quality of life was evaulated using the European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30), physical activity level using the International Physical Activity Questionnaire (IPAQ), anxiety and depression status using the Hospital Anxiety and Depression Scale (HADS), and quality of life in terms of health using the Nottingham Health Profile.

Results: The duration of ADT use in patients with high-risk and intermediate-risk was mean 24.6 months and 6.3 months, respectively. However, the duration of ADT use did not significantly affect the quality of life, physical activity, anxiety, and depression levels (P > .05). Binary logistic regression analysis showed that BMI was negatively associated with moderate PA in unadjusted analysis [odds ratio (OR): 0.87; 95% confidence interval (CI), 0.75-1.00]. According to the results of the adjusted analysis, being moderately physically active was positively associated with the functional subscale of the EORTC-QLQ-C30 (OR: 1.10; CI: 1.01-1.20).

Conclusion: The study revealed that short-term or long-term use of ADT causes similar side effects. The intermediate-risk status of the patients did not result in a significant reduction in ADT side effects.

Cite this article as: Feyzioğlu Ö, Dinçer S, Özdemir AE, Öztürk Ö, Açan Hİ. Effects of androgen deprivation therapy duration on health-related quality of life, physical activity, and anxiety and depression levels in patients with intermediate- and high-risk prostate cancer. Arch Health Sci Res. 2024;11(1):14-19.